Late-stage Alzheimer’s drug targets two key culprits

Researchers involved in the ambitious development program for bapineuzumab say that the amyloid-targeting drug also attacks a second key culprit implicated in the mind-wasting disease. Patients enrolled in two mid-stage clinical trials for bapineuzumab demonstrated its effect in lowering the level of tau, a toxic protein that spurs the development of brain tangles. "If you lower tau levels, it's logical to assume that this will have an effect on cognition," Dr. Kaj Blennow of the University of...